Markets have largely batted away the black swan of a Trump victory, but the spectacle of risk and...

The main Q4 topics for equities include the US presidential election, a potential rate hike in...

Joe Neighbour has been tracking GlaxoSmithKline, a big pharma stock that seems to be in a...

The Danish large cap OMX Copenhagen 20 index has risen more than 40% this year outperforming most...

Expect them to be disappointing. That's what Saxo's Peter Garnry predicts ahead of...

This week the New York Times, in an editorial, urged US lawmakers to legalise marijuana. Some...

Serge Berger suggests buying Biogen, a biotech firm which has reported sales of its Multiple...

It’s been revealed that talks between US agricultural giant Monsanto and its rival Syngenta have...

AstraZeneca’s stock price tumbled 14 percent on Monday morning after the company rejected...

As the Astra Zeneca Pfizer deal gets more bad tempered and political, what are the side effects...

Leading Bio tech firms, have seen around thirty percent growth in the last year and prospects...

What next in the drama surrounding the proposed merger of pharmaceutical giants Pfizer and...